( Studies Show Increased Enzyme Levels in...)Amicus Therapeutics Presents Preclinical Data from Studies of,Plicera for Gaucher Disease,Health

CRANBURY, N.J., March 20, 2007 /PRNewswire/ -- Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of a range of human genetic diseases, announced today that it will present the results of preclinical studies of Plicera(TM) (isofagomine tartrate, AT2101) for Gaucher disease at the of Medical Genetics (ACMG) annual meeting March 21-25 in Nashville, TN. The data demonstrate the ability of Plicera to increase levels of the target enzyme in cells derived from a patient with the N370S mutation and in mice that express the L444P mutation. The N370S and the L444P are the two most common mutations associated with Gaucher disease. Additional data from both studies will also be presented.

Plicera is designed to selectively bind to and stabilize GCase, the enzyme deficient in Gaucher disease. This deficiency leads to lysosomal accumulation of glucocerebroside inside certain cells, which is believed to cause the various symptoms of Gaucher disease. Plicera facilitates proper trafficking of the enzyme to the lysosomes, the compartments in the cell where it is needed to break down glucocerebroside.

The following is a summary of the preclinical Plicera data being presented at ACMG.

    - In vitro exposure to Plicera increased transport of GCase to the

      lysosomes in cells derived from a patient with the N370S mutation.

      Once in the lysosome, the enzyme was stable and active for more than 3

      days after Plicera was removed. The N370S is the most common mutation

      associated with Gaucher disease in the Western world.  These studies

      were published in the September 12, 2006 issue of the Proceedings of the

      National Academy of Sciences (PNAS).


    - Oral administration of Plicera resulted in a dose-dependent increase of
'"/>




Page: 1 2 3 
Related medicine technology :

1. Amicus Therapeutics Presents Positive Results From Phase 1 Clinical
Studies of Plicera for Gaucher Disease
2. Amicus Therapeutics Presents Data From Preclinical and Phase 1
Studies of Amigal for Fabry Disease
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement
of Interim Pixantrone Study Results
4. Halozyme Therapeutics Enhanze Technology Large Protein Molecule
Therapeutic Clinical Trial Results Presented at the 34th Annual
Meeting of the Controlled Release Society
5. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of
Action for Ranexa
6. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into
Personalized, Cancer-Targeted Therapeutics
7. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to
Sustained Reductions in Blood Glucose Levels for 6 Months
Post-treatment in Type 2 Diabetes Patients
8. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for
Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical
Study
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II
Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on
Visceral Fat and Insulin Resistance at American Diabetes
Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of
Efaproxyn in Women With Brain Metastases Originating From Breast
Cancer